Selective inhibition of the epidermal growth factor receptor by ZD1839 decreases the growth and invasion of ovarian clear cell adenocarcinoma cells

Clinical Cancer Research

Volumn 8, Issue 7, 2002, Pages 2448-2454

  Fujimura, Masaki ^a   Hidaka, Takao ^a   Saito, Shigeru ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; TYROSINE KINASE RECEPTOR; ANTINEOPLASTIC AGENT; ENDOTHELIAL CELL GROWTH FACTOR; GROWTH PROMOTOR; LYMPHOKINE; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE; SIGNAL PEPTIDE; VASCULOTROPIN; VASCULOTROPIN A;

ADULT; AGED; ANIMAL MODEL; ARTICLE; CANCER INVASION; CELL PROLIFERATION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; TUMOR VOLUME; ADENOCARCINOMA; ANIMAL; CELL CULTURE; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; ENZYME IMMUNOASSAY; IN VITRO STUDY; METABOLISM; MOUSE MUTANT; OVARY TUMOR; PATHOLOGY; PHOSPHORYLATION;

ADENOCARCINOMA, CLEAR CELL; ANIMAL; ANTINEOPLASTIC AGENTS; CELL DIVISION; CYTOKINES; ENDOTHELIAL GROWTH FACTORS; FEMALE; GROWTH SUBSTANCES; HUMAN; IMMUNOENZYME TECHNIQUES; IN VITRO; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MICE; MICE, SCID; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTEIN-TYROSINE KINASE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SUPPORT, NON-U.S. GOV'T; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR CELLS, CULTURED; ANIMALS; HUMANS; PROTEIN-TYROSINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035992453     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Endometrioid and clear cell carcinoma of the ovary. Factors affecting survival
2. Clear cell carcinoma of the ovary: A clinicopathologic study with review of the literature
3. Clear cell adenocarcinoma of the ovary: A clinical analysis and comparison with serous carcinoma
4. Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas
5. Clear cell carcinoma of the ovary: Characterization of its CD44 isoform repertoire
6. Absence of estrogen receptor-α expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid and mucinous adenocarcinoma
7. Estrogens, the immune response and autoimmunity
8. Estrogen regulation of tansforming growth factor-α in ovarian cancer
9. Importance of transforming growth factor α/epidermal growth factor receptor autocrine growth mechanism in an ovarian cancer cell line in vivo
10. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
11. Establishment and characterization of a CA-125-producing human ovarian clear cell carcinoma cell line
12. Selection of human carcinoma cells with high dissemination potential by repeated passage of the cells in vivo into nude mice, and involvement of Le(x)-determinant in the dissemination potential
13. Establishment of a human ovarian clear-cell carcinoma cell line (HAC-2 cell) in vitro
14. Induction of autocrine factor inhibiting cell motility from murine B16-BL6 melanoma cells by α-melanocyte stimulating hormone
15. 4-[3,3-Bis(trimethylsilyl) benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals
16. The therapy of human tumors in athymic (nude) mice
17. Long-term results and prognostic factors in patients with epithelial ovarian cancer
18. Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: A dose-finding study
19. Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum
20. Neoadjuvant chemotherapy in advanced ovarian cancer
21. Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy
22. Clear cell carcinoma of the ovary: Poor prognosis compared to serous carcinoma
23. BRCA1 inhibition of estrogen receptor signaling in transfected cells
24. Differential expression of estrogen receptor-α and -β messenger RNAs as a potential marker of ovarian carcinogenesis
25. Estrogen receptor α (ER-β) and β (ER-β) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: Down-regulation of ER-β in neoplastic tissues
26. Significance of epidermal growth factor receptor in advanced ovarian cancer
27. Occurrence of epidermal growth factor receptors in benign and malignant ovarian tumors and normal ovarian tissues: An immunohistochemical study
28. Epidermal growth factor receptor in ovarian tumours: Correlation of immunohistochemistry with ligand binding assay
29. EGF-R and PCNA expression in ovarian carcinomas-correlation with classic prognostic factors
30. Transforming growth factor-alpha promotes tumor markers secretion from human ovarian cancers in vitro
31. Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53, Ki67, and tumor necrosis factor α in epithelial ovarian cancer
32. EGFR and steroid receptors in ovarian carcinoma: Comparison with prognostic parameters and outcome of patients
33. Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer
34. Growth inhibition of human lung adenocarcinoma cells by antibodies against epidermal growth factor receptor and by ganglioside GM3: Involvement of receptor-directed protein tyrosine phosphatase(s)
35. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN 5
36. The inhibitory effect of an EGF receptor-specific tyrosine kinase inhibitor on pancreatic cancer cell lines was more potent than inhibitory antibodies against receptors for EGF and IGF 1
37. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner
38. Inhibition of transforming growth factor α (TGF-α)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868
39. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
40. Apoptosis and growth inhibition of head and neck tumor cell line induced by epidermal growth factor receptor tyrosine kinase inhibitor
41. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines
42. Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells
43. Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide
44. Preferential inhibition of glioblastoma cells with wild-type epidermal growth factor receptors by a novel tyrosine kinase inhibitor ethyl-2,5-dihydroxycinnamate
45. Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (Iressa™), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)